Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
HOBBS HELENDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007234 · doc4.xml · derivative · entry 1 HOBBS HELEN · CIK 0001537057 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,468.571 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007235 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,069.14 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
LITTMAN DAN R.Director
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007236 · doc4.xml · derivative · entry 1 LITTMAN DAN R. · CIK 0001733004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625.889 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007237 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,486.42 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:31 UTC |
NORA JOHNSON SUZANNE MDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007238 · doc4.xml · derivative · entry 1 NORA JOHNSON SUZANNE M · CIK 0001310264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,712.313 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2019 Filed Apr 26, 2019 21:32 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 4,859.884 | $39.61 | $192,500.01 |
DisclosureSEC source: 0001225208-19-007239 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,901.961 Underlying: Common Stock · 4,859.884 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:17 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 24 | $42.09 | $1,010.16 |
DisclosureSEC source: 0001225208-19-006855 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,864 Underlying: Common Stock · 24 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:17 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $42.09 | $168.36 |
DisclosureSEC source: 0001225208-19-006856 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,841 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:19 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 45 | $42.09 | $1,894.05 |
DisclosureSEC source: 0001225208-19-006858 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,430 Underlying: Common Stock · 45 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 23:18 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $42.09 | $420.90 |
DisclosureSEC source: 0001225208-19-006857 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,589 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 10, 2019 Filed Apr 11, 2019 20:05 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 174 | $42.73 | $7,435.02 |
DisclosureSEC source: 0001225208-19-006645 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,839 Underlying: Common Stock · 174 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 10, 2019 Filed Apr 11, 2019 20:05 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 378 | $42.73 | $16,151.94 |
DisclosureSEC source: 0001225208-19-006646 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,384 Underlying: Common Stock · 378 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 10, 2019 Filed Apr 11, 2019 20:05 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 27 | $42.73 | $1,153.71 |
DisclosureSEC source: 0001225208-19-006647 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,837 Underlying: Common Stock · 27 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 10, 2019 Filed Apr 11, 2019 20:05 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 148 | $42.73 | $6,324.04 |
DisclosureSEC source: 0001225208-19-006648 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,578 Underlying: Common Stock · 148 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 2,215 | $42.88 | $94,979.20 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 23 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,094 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 1,581 | $42.90 | $67,824.90 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 22 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,309 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 1,230 | $42.80 | $52,644.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 21 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,890 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 1,134 | $42.85 | $48,591.90 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 20 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,120 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 1,100 | $42.82 | $47,102.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 19 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,254 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 800 | $42.79 | $34,232.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 18 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,354 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 713 | $42.84 | $30,544.92 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 17 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,154 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 703 | $42.81 | $30,095.43 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 16 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,867 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 658 | $42.83 | $28,182.14 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 15 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,570 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 623 | $42.91 | $26,732.93 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 14 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,228 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 600 | $42.76 | $25,656.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 13 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,851 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 600 | $42.77 | $25,662.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 12 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,451 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 560 | $42.89 | $24,018.40 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 11 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,051 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 555 | $42.87 | $23,792.85 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 10 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,611 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 547 | $42.86 | $23,444.42 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 9 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,166 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 300 | $42.78 | $12,834.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 8 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,713 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 294 | $42.67 | $12,544.98 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 7 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,013 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 200 | $42.59 | $8,518.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 6 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,307 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 152 | $42.92 | $6,523.84 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,507 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 128 | $42.60 | $5,452.80 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 4 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,659 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 107 | $42.61 | $4,559.27 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 3 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,787 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 100 | $42.74 | $4,274.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,894 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 19:05 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 100 | $42.93 | $4,293.00 |
DisclosureSEC source: 0001225208-19-006048 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,994 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2019. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 23:00 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 1,015.423 | $42.47 | $43,125.01 |
DisclosureSEC source: 0001225208-19-005957 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,550.16 Underlying: Common Stock · 1,015.423 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 23:00 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 809.395 | $42.47 | $34,375.01 |
DisclosureSEC source: 0001225208-19-005958 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,209.256 Underlying: Common Stock · 809.395 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 23:00 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 1,103.72 | $42.47 | $46,874.99 |
DisclosureSEC source: 0001225208-19-005959 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,626.536 Underlying: Common Stock · 1,103.72 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 23:00 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 985.99 | $42.47 | $41,875.00 |
DisclosureSEC source: 0001225208-19-005960 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,042.077 Underlying: Common Stock · 985.99 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:05 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 24 | $42.47 | $1,019.28 |
DisclosureSEC source: 0001225208-19-006049 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,665 Underlying: Common Stock · 24 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:05 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $42.47 | $127.41 |
DisclosureSEC source: 0001225208-19-006050 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,811 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:06 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 41 | $42.47 | $1,741.27 |
DisclosureSEC source: 0001225208-19-006051 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,006 Underlying: Common Stock · 41 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:06 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $42.47 | $424.70 |
DisclosureSEC source: 0001225208-19-006052 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,430 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 22:37 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 570 | $41.78 | $23,814.60 |
DisclosureSEC source: 0001225208-19-005428 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,644 Underlying: Common Stock · 570 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 22:37 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 33 | $41.78 | $1,378.74 |
DisclosureSEC source: 0001225208-19-005429 · doc4.xml · derivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,808 Underlying: Common Stock · 33 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 22:37 UTC |
JOHNSON RADY AExecutive Vice President
|
SaleCommon Stock | 8,700 | $41.13 | $357,831.00 |
DisclosureSEC source: 0001225208-19-005429 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,797 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 22:37 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 474 | $41.78 | $19,803.72 |
DisclosureSEC source: 0001225208-19-005430 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,967 Underlying: Common Stock · 474 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 22:37 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 260 | $41.78 | $10,862.80 |
DisclosureSEC source: 0001225208-19-005431 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,422 Underlying: Common Stock · 260 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.